A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers

October 25, 2015 updated by: National Taiwan University Hospital

Diabetes mellitus is a common disease with much impact on human's health and is related to osteoporosis. But the mechanism remains unclear. The foreign researches revealed thiazolidinedione (TZD) would increase the risk of osteoporosis and bone fracture, specially elderly women. However, it is still controversial in terms of the youth and men. In Taiwan,there is few related study to analyze the relationship between TZD and steoporosis.

This is a multicenter randomized controlled study.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

Diabetes mellitus is a common disease with much impact on human's health and is related to osteoporosis. But the mechanism remains unclear. The foreign researches revealed thiazolidinedione (TZD) would increase the risk of osteoporosis and bone fracture, especially elderly women. However, it is still controversial in terms of the youth and men. In Taiwan, there is few related study to analyze the relationship between TZD and osteoporosis.

This is a multicenter randomized controlled study.This study will recruit adult (age ³40 years) type 2 diabetes patients who is on metformin (³1500mg/day) currently with recent HbA1c between 7.0~8.5%.Patient who has history of macular edema, congestive heart failure (NYHA Fc III, IV), chronic renal failure (stage IV, V), AST or ALT above 2.5 times upper limit, Medical history of endocrinopathies, osteoporosis with bone fracture, cancer will be excluded. Current bone fracture undergoing treatment, pregnancy, breast feeder will also be excluded.

This is a 3-year project and will enroll 160 eligible volunteers who are to randomized into group A and B (80 in each). During the next 48 weeks group A and B will receive metformin+pioglitazone and metformin+linagliptin respectively. Blood sugar, renal, and liver functions will be examined every 12 weeks. Calcium, phosphorus, vitamin D level, and bone turnover markers (N-terminal propeptide of type 1 procollagen, bone-specific alkaline phosphatase, osteocalcin, serum C- telopeptide, type 5 tartrate resistant acid phosphatase (TRAP), pyridinoline and deoxypyridinoline crosslinks) will be checked each 6 months.

All the blood samples will be sent to one core laboratory center. The within-group differences will be examined by repeated-measure ANOVA. The between-group differences will be examined by Student's t test.

Study Type

Interventional

Enrollment (Anticipated)

160

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • 1. Males or females ≥ 40 years of age at Visit 1and females in postmenopause for one year

  • Documentation of type 2 diabetes mellitus as evidenced by one or more of the following criteria:

    1. With typical symptoms and random blood sugar ≥ 200 mg/dl
    2. 8-hour fasting blood sugar ≥ 126 mg/dl
    3. Oral glucose tolerance test ≥ 200 mg/dl
    4. HbA1c≥ 6.5%
  • Only receiving oral anti-diabetic drugs (excluding TZDs or DPP-4 inhibitors) till visit 1 at least 3 months, and the HbA1c is between 7.0~8.5 % in recent 3 months.
  • Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study.

Exclusion Criteria:

  • DM on oral anti-diabetic drugs less than 3 months.
  • Receiving treatment of TZDs or DPP-4 inhibitors prior to this study.
  • Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
  • AST, ALT over 2.5 times of the upper limit.
  • Chronic kidney disease, stage 4 and 5.
  • Congestive heart failure, NYHA class III, IV
  • History of osteoporosis.
  • History of diseases known to affect bone metabolism:

Abnormal thyroid function or history of hyperthyroidism, Cushing's syndrome, hypogonadism, acromegaly, history of hypopituitarism or status post pituitary surgery and/or radiotherapy, hematopoietic disorders.

  • History of moderate to severe Diabetic macular edema (DME)
  • History of moderate to severe diabetic retinopathy.
  • History of fracture over lumbar spine or hip joint or femoral head or forearm or any site of bone fracture undergoes treatment currently.
  • Who had taken any of the following medications prior to screening:

Corticosteroid, heparin, anticonvulsants, aluminum-containing antacid, proton pump inhibitor, immunosuppressant user within 3 months. Bisphosphonate, systemic fluoride treatment, PHT analogue, calcitonin, Denosumab, Strontium ranelate, hormone replacement therapy (androgen/estrogen/progesterone, thyroxine, growth hormone), selective estrogen receptor modulator /SERM (Tamoxifene, Raloxifene), selective tissue estrogenic activity regulator /STEAR (Tibolone), aromatase inhibitors within 1 year.

  • History of cancer.
  • Bed-ridden patients.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Pioglitazone
Pioglitazone 30 mg once daily will be administered orally for total 48 weeks.
Drug: Pioglitazone
Pioglitazone 30mg/tablet once daily
Other Names:
  • Actos
Active Comparator: Linagliptin
Linagliptin 5 mg once daily will be administered orally for total 48 weeks.
Drug: Linagliptin
Linagliptin 5mg/tablet once daily
Other Names:
  • Trajenta

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from baseline in bone turnover markers
Time Frame: Screen, Week 24, 48
The primary objective is to assess the effect of TZD on skeleton as measured bone turnover markers over the 12 months treatment period.
Screen, Week 24, 48

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from baseline in Estimated glomerular filtration rate( eGFR)
Time Frame: Screen, Week 24, 48
The objective is to assess the effect of TZD on kidney by measurement of Estimated glomerular filtration rate( eGFR) over the 12 months treatment period.
Screen, Week 24, 48
Change from baseline in renal function-serum Creatinine (Cr) level
Time Frame: Screen, Week 24, 48
The secondary objective is to assess the effect of TZD on kidney by measurement of doubling time of serum Creatinine (Cr) level and urine biomarkers over the 12 months treatment period.
Screen, Week 24, 48
Change from baseline in renal function-Urine Albumin-to-Creatinine Ratio(UACR)
Time Frame: Screen, Week 24, 48
The secondary objective is to assess the effect of TZD on kidney by measurement of doubling time of Urine Albumin-to-Creatinine Ratio(UACR) and urine biomarkers over the 12 months treatment period.
Screen, Week 24, 48
Change from baseline in urine biomarkers
Time Frame: Screen, Week 24, 48
The secondary objective is to assess the effect of TZD on kidney by measurement of urine biomarkers over the 12 months treatment period.
Screen, Week 24, 48

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

National Taiwan University Hospital

Investigators

  • Principal Investigator: Chin-Hsiao Tseng, MD, PhD, Department of Medicine,National Taiwan University Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2015

Primary Completion (Anticipated)

July 1, 2017

Study Completion (Anticipated)

December 1, 2017

Study Registration Dates

First Submitted

April 7, 2015

First Submitted That Met QC Criteria

April 28, 2015

First Posted (Estimate)

April 29, 2015

Study Record Updates

Last Update Posted (Estimate)

October 27, 2015

Last Update Submitted That Met QC Criteria

October 25, 2015

Last Verified

October 1, 2015

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 201312136MIND

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diabetes Mellitus

Clinical Trials on Pioglitazone

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malaysia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe